SOURCE: IsoRay, Inc.

IsoRay, Inc.

June 29, 2015 08:30 ET

IsoRay's Cesium-131 Selected by Chicago Prostate Cancer Center for Use in the Launch of a Study of the Focal Treatment of Prostate Cancer

Cesium-131 Use in Prostate Focal Cancer Treatment Hopes to Minimize Side Effects and Improve Patient Quality of Life

RICHLAND, WA--(Marketwired - Jun 29, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that Dr. Brian J. Moran, Director of Chicago Prostate Cancer Center in Westmont, Illinois, has initiated a study of focal prostate cancer treatment using Cesium-131 brachytherapy.

Focal therapy is treatment directed solely at the malignancy and its immediate surrounding tissue, rather than the entire gland or organ that is involved. The goal of focal therapy for prostate cancer is to eliminate the targeted cancer while sparing men the side effects that often come with whole gland treatment.

Dr. Moran stated, "I think the mindset of prostate cancer treatment until today has been all or none. In other words, one size fits all and you do either whole gland radiation or surgical removal. The medical community has been very slow to evaluate the concept of focal therapy for the treatment of prostate cancer."

Dr. Moran plans to build on observations derived from his previous focal cases and further noted, "Our initial experience with focal therapy was patient-driven by individuals who were deciding between active surveillance and full gland treatment. We initially embarked on this approach approximately 10 years ago. Over time, it became very apparent that the results were encouraging. Cancer control rates were excellent and toxicity was negligible. This should be the goal of any cancer therapy: to eradicate the malignancy while not impairing quality of life. Naturally, patient selection is of paramount importance when choosing focal therapy to treat prostate cancer. For the past 10 years, we have been offering a transperineal mapping biopsy that is very comprehensive. The information using this technique allows us to identify the exact location of the cancer within the prostate."

Dr. Moran's focal study will employ Cesium-131 radioactive seed implantation to the affected area of the prostate. Dr. Moran further noted, "We chose Cesium-131 due to its generous energy and homogeneous dose. This minimizes potential cold spots and offers adequate margin to the area being treated."

The study is currently open for enrollment, and will analyze patterns of response in a structured fashion.

IsoRay Chairman and CEO Dwight Babcock commented, "We are pleased that a growing number of leading physicians and medical institutions are embracing the use of Cesium-131 in fighting cancers throughout the body. We continue to receive inquiries from new physicians and institutions based on recently released peer reviewed publications reporting on the successes of using Cesium-131. Medical professionals rely on these publications to further their practice and learn about new leading edge products."

IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.

About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting Join us on Facebook/Isoray. Follow us on Twitter @Isoray.

Safe Harbor Statement

Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of our products will increase or continue, whether awareness and adoption of our products in the medical community will continue or increase, whether ultimate study results will be favorable, whether current and future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact Information